206650 — EuBiologics Co Balance Sheet
0.000.00%
- KR₩472bn
- KR₩462bn
- KR₩96bn
- 84
- 33
- 73
- 72
Annual balance sheet for EuBiologics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 53,088 | 31,545 | 11,044 | 9,897 | 22,854 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 6,383 | 3,917 | 5,547 | 12,099 | 12,076 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 71,407 | 53,720 | 41,139 | 41,764 | 83,143 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 68,538 | 70,046 | 72,815 | 70,096 | 76,100 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 155,955 | 150,438 | 162,066 | 151,806 | 202,085 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 35,197 | 17,282 | 24,624 | 25,699 | 43,044 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 59,079 | 30,439 | 37,556 | 40,433 | 70,052 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 96,877 | 119,999 | 124,510 | 111,373 | 132,033 |
Total Liabilities & Shareholders' Equity | 155,955 | 150,438 | 162,066 | 151,806 | 202,085 |
Total Common Shares Outstanding |